Showing 1-10 of 20 results for "".
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He recently served as President and General Manager for Galderma Laboratories, North America. Prior to that, Mr. Zavodnick led commercia…
- Industry Vet Todd Zavodnick Joins Dermavent Sciences as CEOhttps://practicaldermatology.com/news/industry-vet-todd-zavodnick-joins-dermavent-sciences-as-ceo/2457506/Todd Zavodnick is the new Chief Executive Officer of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences. "It is an honor to join Dermavant at such an exciting time in the company's growth," says Mr. Zavodnick in a news release. "Medical dermatology is a therapeutic area in ne…
- Todd Zavodnickhttps://practicaldermatology.com/profiles/todd-zavodnick/OE6nM2/
- Report: Dermavant Files for $100M IPOhttps://practicaldermatology.com/news/report-dermavant-files-for-100m-ipo/2460043/Dermavant Sciences last week filed with the SEC to raise up to $100 million in an initial public offering, Renaissance Capital reports. The company, a dermatology-focused subsidiary of Roivant Sciences, has made several key appointments lately, including naming Todd Zavodnick Chief Executive Offic…
- Nancy Beesley Joins Dermavant Board of Directorshttps://practicaldermatology.com/news/nancy-beesley-joins-dermavant-board-of-directors/2461101/Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseases. “Nancy is an es…
- Dermavant Launches First Commercial for VTAMAhttps://practicaldermatology.com/news/dermavant-launches-first-commercial-for-vtama/2461441/Dermavant Sciences launched its first commercial as part of a national, multimedia, direct-to-consumer advertising campaign for VTAMA (tapinarof) cream, 1%. Inspired by the stories of real patients, the “Topical Uprising” campaign focuses on the patient journey — tapping into the frustrations of l…
- Dermavant Submits NDA for Tapinarof for PsOhttps://practicaldermatology.com/news/dermavant-submits-nda-for-tapinarof-for-pso/2460820/Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severe plaque psoriasis in adult patients. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and…
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at Gal…
- Galderma Introduces ASPIRE Loyalty Program for the Aesthetic Industryhttps://practicaldermatology.com/news/galderma-introduces-aspire-loyalty-program-for-the-aesthetic-industry/2458936/Galderma launched ASPIRE Galderma Rewards, a new loyalty program for its aesthetic brands. ASPIRE is unique in that it serves both both US healthcare professionals and consumers in one integrated program. ASPIRE rewards its members with significant savings across the entire aesthetic product line …
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines. Dustin Sjuts is the new Vice President of Strategy and Sales, Aestheti…
- Prev
- Next